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Abstract
There is abundant evidence that extracellular ATP and other nucleotides have an important role in pain signaling at both
the periphery and in the CNS. At first, it was thought that ATP was simply involved in acute pain, since ATP is released
from damaged cells and excites directly primary sensory neurons by activating their receptors. However, neither blocking
P2X/Y receptors pharmacologically nor suppressing the expression of P2X/Y receptors molecularly in sensory neurons or
in the spinal cord had an effect on acute physiological pain. The focus of attention now is on the possibility that
endogenous ATP and its receptor system might be activated in pathological pain states, particularly in neuropathic pain.
Neuropathic pain is often a consequence of nerve injury through surgery, bone compression, diabetes or infection. This
type of pain can be so severe that even light touching can be intensely painful; unfortunately, this state is generally
resistant to currently available treatments. An important advance in our understanding of the mechanisms involved in
neuropathic pain has been made by a recent work demonstrating the crucial role of ATP receptors (i.e., P2X3 and P2X4
receptors). In this review, we summarize the role of ATP receptors, particularly the P2X4 receptor, in neuropathic pain.
The expression of P2X4 receptors in the spinal cord is enhanced in spinal microglia after peripheral nerve injury, and
blocking pharmacologically and suppressing molecularly P2X4 receptors produce a reduction of the neuropathic pain
behaviour. Understanding the key roles of ATP receptors including P2X4 receptors may lead to new strategies for the
management of neuropathic pain.
Abbreviations: IL-1b– interleukin-1b; IL-6–interleukin-6; MAPK–mitogen-activated protein kinase; PPADS–pyridoxal-
phosphate-6-azophenyl-2¶,4¶-disulphonic acid; TNF-a –tumor necrosis factor-a; TNP-ATP–2¶,3¶-0-(2,4,6-trinitrophenyl)
adenosine 5¶-triphosphate
Introduction
Although the possibility of extracellular ATP being able to
evoke pain in the periphery was raised about 30 years ago
[1, 2], significant advances in our understanding of the
molecular mechanisms by which ATP causes pain have
been made quite recently by the discovery of cell-surface
receptors for detecting extracellular ATP, and other nucleo-
tides, via P2 receptors on sensory neurons [3Y7]. In a subset
of primary afferent sensory neurons, ATP or its analogues
produce electrophysiological and biological responses via
ligand-gated ion-channel receptors, namely P2X receptors
(P2XRs) [8Y13], and G protein-coupled receptors, namely
P2Y receptors (P2YRs) [14Y19]. The P2XR and P2YR
subclasses have been further divided into seven (P2X1Y7Rs)
and eight (P2Y1,2,4,6,11Y14Rs) subtypes, respectively [6, 20].
m R N Aa n dp r o t e i nf o rb o t hP 2 X R sa n dP 2 Y R sa r e
expressed in sensory neurons, but accumulating evidence
using gene deletion methods, antisense technologies, and
selective receptor antagonists now suggests that the molec-
ular targets of ATP on primary sensory neurons could be
P2X3Rs, P2X2/3Rs (heteromultimeric P2X2 and P2X3
receptors), P2Y1Rs and P2Y2Rs [11, 17, 19, 21Y26]. ATP
responses evoked via these receptors in primary sensory
neurons could code for the sensation of pain in vivo in
laboratory animals [5Y7, 11, 12, 23, 24, 26Y35]. All cells
contain millimolar levels of ATP and release ATP into the
extracellular milieu when tissues are damaged [36] or
stimulated mechanically [37]. The released ATP activates
neighboring sensory nerve endings via P2X and P2YRs
[36, 37]. These make ATP an interesting candidate for a
tissue-damage signal at the periphery that may activate
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dorsal horn of the spinal cord, ATP, presumably released
from primary afferent central terminals [39], modulates
excitatory (glutamatergic) and inhibitory (GABAergic and
glycinergic) neurotransmission in dorsal horn neurons
[40Y47]. Activation of P2XRs in the spinal cord enhances
pain behaviour [29, 48, 49], suggesting that ATP has a role
in pain processing in the spinal cord as well. However,
blocking P2XRs or P2YRs pharmacologically or suppress-
ing their expression molecularly in sensory neurons or in
the spinal cord had little effect on acute physiological pain
evoked by heat or mechanical pressure in normal animals
[23, 24, 26, 30, 31, 33]. It thus seems likely that endogenous
ATP and its receptors system may be activated rather in
pathological pain states, particularly in neuropathic pain,
than in normal conditions [26, 30, 31, 50].
Neuropathic pain, which often develops when nerves are
damaged through surgery, bone compression, diabetes or
infection, is a type of pathological pain that does not resolve
even when the overt tissue damage has healed [51Y53].
Neuropathic pain can be so severe that even light contact
with clothing can be intensely painful (tactile allodynia Y an
abnormal hypersensitivity to innocuous stimuli) and is
relatively resistant to most current treatments. Accumulating
evidence concerning how peripheral nerve injury creates
neuropathic pain has suggested that molecular and cellular
alterations in primary sensory neurons and in the spinal
dorsal horn after nerve injury have important role in the
pathogenesis of neuropathic pain [51Y53]. While there is an
increasing body of evidence suggesting that P2X3Rs in
primary sensory neurons have a role in neuropathic pain
[26, 30, 31, 54, 55], otherP2XR and P2YR subtypes are also
beginning to be investigated in terms of their changes in
expression using cDNA microarray [56Y58]. Recently, we
revealed that the P2X4R subtype in the spinal cord is
required for the expression of neuropathic pain [59].
Importantly, the expression of P2X4R in the spinal cord is
enhanced, and this is highly restricted to microglia that are
activated after nerve injury. Until recently, glial cells were
generallyconsideredtoserve primarilyhousekeepingrolesin
thenervoussystem,butthatstudydirectlyimplicatedactivated
glia,particularlymicroglia,inthepathogenesisofneuropathic
pain [59]. Here we review the progress in the current
understanding of how the ATP receptor in spinal microglia
participate in the pathophysiology of neuropathic pain.
Microglia and nerve injury-induced pain
Glial cells make up over 70% of the total cell population in
the CNS and are classified into astrocytes, oligodendro-
cytes and microglia. In the adult, microglia are ubiquitous-
ly distributed throughout the CNS and represent a
morphologically unique type of cell; under normal con-
ditions, microglia have a small soma bearing thin and
branched processes [60, 61]. Once activated by neuronal
injury, trauma, ischemia, infection, or neurological dis-
eases, microglia show a stereotypic program of changes in
morphology, gene expression, function and number
[60Y62]. Activated microglia change their morphology
from a resting, ramified shape into an active, amoeboid
shape. The changes in expression of cell-surface molecules
(i.e., complement receptor 3, which is recognized by the
antibody OX42) and in morphology are widely used as the
key diagnostic markers of activated microglia [60, 61].
Clinical evidence that neuropathic pain results from
damage to peripheral nerves in humans led to the
development of a variety of models for studying neuro-
pathic pain in laboratory animals. In most animal models
of neuropathic pain which have been intensively studied so
far peripheral nerves are directly damaged [63Y67].
Evidence from studies using such models has revealed that
peripheral nerve injury leads to a dramatic change in
microglia within the spinal dorsal horn [68Y72]. Within the
first 24 h after peripheral nerve injury, spinal microglia
become hypertrophic in their short and thick processes
[68]. This is followed by a burst proliferation of microglia
with a peak at around 2Y3 days after the nerve injury [73].
Activated microglia exhibit upregulated OX42 labeling in
the dorsal horn [68, 70Y72, 74], which starts to increase as
early as 1 day after nerve injury and peaks at around 14
days [70]. The temporal pattern of OX42 upregulation in
the dorsal horn correlated with that of the development of
tactile allodynia [70], suggesting the role of microglia in
neuropathic pain. While there have been many studies
showing that activation of microglia in the dorsal horn is
correlated with the development of pain hypersensitivity in
a wide variety of nerve injury models [68, 70Y72, 74, 75],
until recently it remained an open question whether spinal
microglia play a causal role in neuropathic pain behaviour.
P2X4Rs in spinal microglia are necessary and sufficient
for neuropathic pain
A clue to identifying P2X4Rs in the spinal cord as being
required for neuropathic pain first came from pharmacolog-
ical investigations of pain behaviour after nerve injury using
the P2XR antagonists TNP-ATP and PPADS [59]. We
found that the marked tactile allodynia that develops
following injury of a spinal nerve was reversed by acutely
administering TNP-ATP intrathecally but was unaffected by
administering PPADS. TNP-ATP had no effect on acute
pain behaviour in the uninjured state nor on motor
behaviour. From the pharmacological profiles of TNP-ATP
and PPADS, it was inferred that tactile allodynia depends
upon P2X4Rs in the spinal cord. The expression of P2X4R
protein, normally low in the naı ¨ve spinal cord, progressively
increased in the days following nerve injury with a time-
course parallel to that of the development of tactile
allodynia. Immunohistochemical analysis demonstrated that
many small cells in the dorsal horn on the side of the nerve
injury were intensely positive for P2X4Rp r o t e i n .T h e s e
cells were identified as microglia rather than neurons or
astrocytes by double immunolablelling using cell-specific
markers. The cells expressing P2X4R in the nerve-injured
side of the dorsal horn were more numerous than under
96 K. Inoue et al.control conditions and showed high levels of OX42 labeling
and morphological hypertrophy, all of which are character-
istic markers of activated microglia. Moreover, it was found
that reducing the upregulation of P2X4R protein in spinal
microglia by means of intrathecally administered antisense
oligodeoxynucleotide targeting P2X4R prevented the devel-
opment of the nerve injury-induced tactile allodynia.
Collectively, this evidence implies that P2X4Rs activation
is necessary for pain hypersensitivity following nerve injury,
and that microglia are required for this hypersensitivity
since the expression of these receptors in the dorsal horn is
restricted to this type of cell.
The sufficiency of P2X4R activation in microglia for the
development of allodynia was demonstrated by intrathecal
administration of activated, cultured microglia in which
these receptors had been stimulated in vitro by ATP [59].
In otherwise naı ¨ve animals, intrathecal administration of
cultured microglia that were preincubated with ATP to
activate P2X4Rs on microglia produced tactile allodynia
progressively over the 3Y5 h following the administration.
In contrast, intrathecal administration of unstimulated
microglia did not cause allodynia nor did administering
vehicle or ATP alone. Microglia also express another
subtype of P2XR, P2X7R, but this receptor subtype appears
Figure 1. Schematic illustration of possible mechanisms by which P2X4R in activated microglia modulate pain signaling in the dorsal horn. Peripheral
nerve injury leads to molecular and cellular alterations in the spinal dorsal horn after nerve injury. Activated microglia after nerve injury increase the
expression of P2X4R. The P2X4R are activated by ATP which is presumably released from primary sensory neurons (or astrocytes), and in turn cause a
rise in the intracellular calcium and activate p38MAPK. These signals lead to the release of bioactive diffusible factors such as cytokines and
chemokines. The diffusible messengers released from microglia may then interact with excitatory and inhibitory synapses of neighboring dorsal horn
neurons and enhance the excitability in dorsal horn neurons, which in turn leads to increased transmission in pain signaling neurons. The enhanced
transmission in the dorsal horn pain network might be due to the facilitation of glutamatergic synaptic transmission or the suppression of GABA/
glycinergic inhibition.
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requires a higher concentration of ATP than used [76, 77]
and because TNP-ATP, which does not affect P2X7Rs [78],
prevents ATP from stimulating microglia to produce
allodynia. Moreover, in rats in which tactile allodynia
was caused by the ATP-stimulated microglia this allodynia
was reversed by administering TNP-ATP [59]. Thus,
stimulation of P2X4Rs is required in the tactile allodynia
caused by ATP-stimulated microglia and this tactile
allodynia therefore resembles that caused by nerve injury.
Collectively, these findings indicate that P2X4R stimula-
tion of microglia is not only necessary for tactile allodynia,
but is also sufficient to cause the allodynia. Furthermore,
this finding makes a strong case that microglia activation is
not simply correlated with neuropathic pain behaviour.
Rather, microglia within the dorsal horn play an active and
ongoing role in the tactile allodynia produced by injury to
peripheral nerves.
Possible mechanisms underlying microglial modulation
of dorsal horn pain signalling
The variety of biological effects produced by ATP in
microglia in in vitro studies using purified microglia in
culture may provide hints towards clarifying the mechanisms
by which microglia produce altered processing of informa-
tion in the spinal cord dorsal horn. We have previously
shown that ATP stimulates the release of plasminogen in a
concentration-dependent manner from 10 to 100 mMw i t ha
peak response at 5Y10 min after the stimulation [79]. ATP
also potently stimulates tumor necrosis factor-a (TNF-a)
release following an increase in the TNF-a mRNA expres-
sion by activating mitogen-activated protein kinases
(MAPKs) [80, 81]. A de novo synthesis and release of
interleukin-6 is also induced by ATP through pathways
mediated by both Ca
2+-dependent protein kinase C and p38
MAPK [82], a member of the MAPK family [83].
Interestingly, we and others have found that nerve injury
leads to persistent activation of p38 MAPK, and, impor-
tantly, that the activation of p38 MAPK in the spinal cord is
entirely restricted to microglia [84, 85]. Furthermore, an
inhibitor of this enzyme, SB203580, administered intrathe-
cally, reverses mechanical allodynia following spinal nerve
ligation [84, 85]. Also, continuous infusion of SB203580
starting before the nerve injury prevents the development of
tactile allodynia [84]. These indicate that p38MAPK could
be an important intracellular event in the development of
nerve injury-induced pain. Moreover, several cytokines such
as IL-1b, IL-6 and TNF-a in the dorsal horn are increased
after nerve lesion [86Y88] and have been implicated in
contributing to nerve-injury pain [75, 86Y90].
The ability of ATP to release cytokines raises the
possibility that microglia might release one, or more,
diffusible factor(s) that act either directly or indirectly on
neurons (Figure 1). Several cytokines have been reported to
alter synaptic transmission in the CNS including the spinal
cord [91Y93]. For example, the exogenous application of
IL-1b enhances NMDA receptor-mediated Ca
2+ responses
via activating tyrosine protein kinase Src [94], which is
known to enhance NMDA receptor activity in dorsal horn
neurons [52, 95]. IL-1b also decreases GABAA receptor-
mediated currents [96]. More recently, Moriguchi et al.
[97] have shown in acute cortical slices that the application
of a microglial-conditioned medium potentiates NMDA
receptor-mediated postsynaptic responses, but not when the
medium is boiled or incubated with proteinase K. Further-
more, they fractionated the medium into six sharp peaks by
anion-exchange chromatography and found that the frac-
tion contained a relatively strong protein band with a
molecular mass of approximately 70 kDa that showed the
most potent enhancing activity on the NMDA receptor-
mediated responses. Although they have not identified the
molecule(s) yet, they suggested that both heat- and
protease-labile molecules released from microglia regulate
NMDA receptor-mediated excitatory synaptic transmission
in the CNS. Thus, diffusible factors released from activated
microglia by activating P2X4Rs may also have modulatory
effects on neurons in the pain processing network within
the dorsal horn (Figure 1).
Conclusion
Damage or injury to peripheral nerve leads to changes in
the spinal cord that cause the activation of microglia (Figure
1). These activated microglia express P2X4R; endogenous
ATP can then activate these receptors and lead to neuro-
pathic pain. Almost all currently known drugs for neuro-
pathic pain were developed to target neurons, and these
drugs do not exhibit adequate therapeutic effects in patients
with neuropathic pain [98]. We expect that efforts to
elucidate how P2X4R signaling in microglia causes neuro-
pathic pain will provide us both with exciting insights into
pain mechanisms and with clues to developing new
therapeutic agents which may fundamentally change the
management of intractable pain. Such strategies could not
have been anticipated based on the prevailing neuron-
centric view of pain.
References
1. Bleehen T, Hobbiger F, Keele CA. Identification of algogenic
substances in human erythrocytes. J Physiol 1976; 262: 131Y49.
2. Bleehen T, Keele CA. Observations on the algogenic actions of
adenosine compounds on the human blister base preparation. Pain
1977; 3: 367Y77.
3. Chen CC, Akopian AN, Sivilotti L et al. A P2X purinoceptor
expressed by a subset of sensory neurons. Nature 1995; 377: 428Y31.
4. Lewis C, Neidhart S, Holy C et al. Coexpression of P2X2 and P2X3
receptor subunits can account for ATP- gated currents in sensory
neurons. Nature 1995; 377: 432Y5.
5. Burnstock G, Wood JN. Purinergic receptors: Their role in nocicep-
tion and primary afferent neurotransmission. Curr Opin Neurobiol
1996;6: 526Y32.
6. Ralevic V, Burnstock G. Receptors for purines and pyrimidines.
Pharmacol Rev 1998; 50: 413Y92.
7. Burnstock G. P2X receptors in sensory neurones. Br J Anaesth 2000;
84: 476Y88.
8. Cook SP, Rodland KD, McCleskey EW. A memory for extracellular
98 K. Inoue et al.Ca
2+ by speeding recovery of P2X receptors from desensitization.
J Neurosci 1998; 18: 9238Y44.
9. Ueno S, Tsuda M, Iwanaga T et al. Cell type-specific ATP-activated
responses in rat dorsal root ganglion neurons. Br J Pharmacol 1999;
126: 429Y36.
10. Li C, Peoples RW, Lanthorn TH et al. Distinct ATP-activated
currents in different types of neurons dissociated from rat dorsal root
ganglion. Neurosci Lett 1999; 263: 57Y60.
11. Tsuda M, Koizumi S, Kita A et al. Mechanical allodynia caused by
intraplantar injection of P2X receptor agonist in rats: Involvement of
heteromeric P2X2/3 receptor signaling in capsaicin-insensitive pri-
mary afferent neurons. J Neurosci 2000; 20: RC90.
12. Chizh BA, Illes P. P2X receptors and nociception. Pharmacol Rev
2001; 53: 553Y68.
13. Dunn PM, Zhong Y, Burnstock G. P2X receptors in peripheral
neurons. Prog Neurobiol 2001; 65: 107Y34.
14. Svichar N, Shmigol A, Verkhratsky A et al. ATP induces Ca
2+
release from IP3-sensitive Ca
2+ stores exclusively in large DRG
neurones. Neuroreport 1997; 8: 1555Y9.
15. Koizumi S, Tsuda M, Shigemoto Y et al. Characterization of P2Y
receptors in cultured rat dorsal root ganglion neurons. Jpn J
Pharmacol 2001; 85: 149.
16. Sanada M, Yasuda H, Omatsu-Kanbe M et al. Increase in
intracellular Ca(2+) and calcitonin gene-related peptide release
through metabotropic P2Y receptors in rat dorsal root ganglion
neurons. Neuroscience 2002; 111: 413Y22.
17. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor
activity by metabotropic ATP receptors as a possible mechanism for
ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 2001;
98: 6951Y6.
18. Molliver DC, Cook SP, Carlsten JA et al. ATP and UTP excite
sensory neurons and induce CREB phosphorylation through the
metabotropic receptor, P2Y2. Eur J Neurosci 2002; 16: 1850Y60.
19. Moriyama T, Iida T, Kobayashi K et al. Possible involvement of
P2Y2 metabotropic receptors in ATP-induced transient receptor
potential vanilloid receptor 1-mediated thermal hypersensitivity. J
Neurosci 2003; 23: 6058Y62.
20. Khakh BS, Bao XR, Labarca C et al. Neuronal P2X transmitter-gated
cation channels change their ion selectivity in seconds. Nat Neurosci
1999; 2: 322Y30.
21. Collo G, North RA, Kawashima E et al. Cloning OF P2X5 and P2X6
receptors and the distribution and properties of an extended family of
ATP-gated ion channels. J Neurosci 1996; 16: 2495Y507.
22. Xiang Z, Bo X, Burnstock G. P2X receptor immunoreactivity in the
rat cochlea, vestibular ganglion and cochlear nucleus. Hear Res
1999; 128: 190Y6.
23. Cockayne DA, Hamilton SG, Zhu QM et al. Urinary bladder
hyporeflexia and reduced pain-related behaviour in P2X3-deficient
mice. Nature 2000; 407: 1011Y5.
24. Souslova V, Cesare P, Ding Y et al. Warm-coding deficits and
aberrant inflammatory pain in mice lacking P2X3 receptors. Nature
2000; 407: 1015Y7.
25. Cockayne DA, Dunn PM, Burnstock G et al. Generation and
electrophysiological characterization of P2X2 and P2X2/P2X3
knockout (KO) mice. Soc Neurosci Abstract 2002; 32: 52.12.
26. Jarvis MF, Burgard EC, McGaraughty S et al. A-317491, a novel
potent and selective non-nucleotide antagonist of P2X3 and P2X2/3
receptors, reduces chronic inflammatory and neuropathic pain in the
rat. Proc Natl Acad Sci USA 2002; 99: 17179Y84.
27. Bland-Ward PA, Humphrey PP. Acute nociception mediated by
hindpaw P2X receptor activation in the rat. Br J Pharmacol 1997;
122: 365Y71.
28. Hamilton SG, Wade A, McMahon SB. The effects of inflammation
and inflammatory mediators on nociceptive behaviour induced by
ATP analogues in the rat. Br J Pharmacol 1999; 126: 326Y32.
29. Tsuda M, Ueno S, Inoue K. In vivo pathway of thermal hyperalgesia
by intrathecal administration of a,b-methylene ATP in mouse spinal
cord: Involvement of the glutamate-NMDA receptor system. Br J
Pharmacol 1999; 127: 449Y56.
30. Dorn G, Abdel’Al S, Natt FJ et al. Specific inhibition of the rat
ligand-gated ion channel P2X3 function via methoxyethoxy-modified
phosphorothioated antisense oligonucleotides. Antisense Nucleic
Acid Drug Dev 2001; 11: 165Y74.
31. Barclay J, Patel S, Dorn G et al. Functional downregulation of P2X3
receptor subunit in rat sensory neurons reveals a significant role in
chronic neuropathic and inflammatory pain. J Neurosci 2002; 22:
8139Y47.
32. Honore P, Kage K, Mikusa J et al. Analgesic profile of intrathecal
P2X(3) antisense oligonucleotide treatment in chronic inflammatory
and neuropathic pain states in rats. Pain 2002; 99: 11Y9.
33. Tsuda M, Shigemoto-Mogami Y, Ueno S et al. Downregulation of
P2X3 receptor-dependent sensory functions in A/J inbred mouse
strain. Eur J Neurosci 2002; 15: 1444Y50.
34. Inoue K, Tsuda M, Koizumi S. ATP induced three types of pain
behaviors, including allodynia. Drug Dev Res 2003; 59: 56Y63.
35. Himaki D, Koizumi S, Mizokoshi A et al. Mechanisms underlying
UTP-evoked mechanical allodynia. J Pharmacol Sci 2003; 94: 189.
36. Cook SP, McCleskey EW. Cell damage excites nociceptors through
release of cytosolic ATP. Pain 2002; 95: 41Y7.
37. Koizumi S, Fujishita K, Inoue K et al. Ca
2+ waves in keratinocytes
are transmitted to sensory neurons: The involvement of extracellular
ATP and P2Y2 receptor activation. Biochem J 2004; 380: 329Y38.
38. Tsuda M, Koizumi S, Inoue K. Role of endogenous ATP at the
incision area in a rat model of postoperative pain. Neuroreport 2001;
12: 1701Y4.
39. Nakatsuka T, Gu JG. ATP P2X receptor-mediated enhancement of
glutamate release and evoked EPSCs in dorsal horn neurons of the
rat spinal cord. J Neurosci 2001; 21: 6522Y31.
40. Li P, Calejesan AA, Zhuo M. ATP P2X receptors and sensory
synaptic transmission between primary afferent fibers and spinal
dorsal horn neurons in rats. J Neurophysiol 1998; 80: 3356Y60.
41. Gu JG, MacDermott AB. Activation of ATP P2X receptors elicits
glutamate release from sensory neuron synapses. Nature 1997; 389:
749Y53.
42. Hugel S, Schlichter R. Presynaptic P2X receptors facilitate inhibitory
GABAergic transmission between cultured rat spinal cord dorsal
horn neurons. J Neurosci 2000; 20: 2121Y30.
43. Jang IS, Rhee JS, Kubota H et al. Developmental changes in P2X
purinoceptors on glycinergic presynaptic nerve terminals projecting
to rat substantia gelatinosa neurones. J Physiol 2001; 536: 505Y19.
44. Rhee JS, Wang ZM, Nabekura J et al. ATP facilitates spontaneous
glycinergic IPSC frequency at dissociated rat dorsal horn interneuron
synapses. J Physiol 2000; 524(Pt 2): 471Y83.
45. Nakatsuka T, Tsuzuki K, Ling JX et al. Distinct roles of P2X
receptors in modulating glutamate release at different primary
sensory synapses in rat spinal cord. J Neurophysiol 2003; 89:
3243Y52.
46. Nakatsuka T, Furue H, Yoshimura M et al. Activation of central
terminal vanilloid receptor-1 receptors and alpha beta-methylene-
ATP-sensitive P2X receptors reveals a converged synaptic activity
onto the deep dorsal horn neurons of the spinal cord. J Neurosci
2002; 22: 1228Y37.
47. Gu JG. P2X receptor-mediated modulation of sensory transmission
to the spinal cord dorsal horn. Neuroscientist 2003; 9: 370Y8.
48. Driessen B, Reimann W, Selve N et al. Antinociceptive effect of
intrathecally administered P2-purinoceptor antagonists in rats. Brain
Res 1994; 666: 182Y8.
49. Okada M, Nakagawa T, Minami M et al. Analgesic effects of
intrathecal administration of P2Y nucleotide receptor agonists UTP
and UDP in normal and neuropathic pain model rats. J Pharmacol
Exp Ther 2002; 303: 66Y73.
50. Dai Y, Fukuoka T, Wang H et al. Contribution of sensitized P2X
receptors in inflamed tissue to the mechanical hypersensitivity revealed
by phosphorylated ERK in DRG neurons. Pain 2004; 108: 258Y66.
51. Woolf CJ, Mannion RJ. Neuropathic pain: Aetiology, symptoms,
mechanisms, and management. Lancet 1999; 353: 1959Y64.
52. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in
pain. Science 2000; 288: 1765Y9.
53. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci
2002; 5 Suppl: 1062Y7.
P2X4 receptors in microglia and neuropathic pain 9954. Tsuzuki K, Kondo E, Fukuoka T et al. Differential regulation of
P2X(3) mRNA expression by peripheral nerve injury in intact and
injured neurons in the rat sensory ganglia. Pain 2001; 91: 351Y60.
55. Kennedy C, Assis TS, Currie AJ et al. Crossing the pain barrier: P2
receptors as targets for novel analgesics. J Physiol 2003; 553:
683Y94.
56. Wang H, Sun H, Della Penna K et al. Chronic neuropathic pain is
accompanied by global changes in gene expression and shares
pathobiology with neurodegenerative diseases. Neuroscience 2002;
114: 529Y46.
57. Xiao HS, Huang QH, Zhang FX et al. Identification of gene
expression profile of dorsal root ganglion in the rat peripheral
axotomy model of neuropathic pain. Proc Natl Acad Sci USA 2002;
99: 8360Y5.
58. Yang L, Zhang FX, Huang F et al. Peripheral nerve injury induces
trans-synaptic modification of channels, receptors and signal path-
ways in rat dorsal spinal cord. Eur J Neurosci 2004; 19: 871Y83.
59. Tsuda M, Shigemoto-Mogami Y, Koizumi S et al. P2X4 receptors
induced in spinal microglia gate tactile allodynia after nerve injury.
Nature 2003; 424: 778Y83.
60. Kreutzberg GW. Microglia: A sensor for pathological events in the
CNS. Trends Neurosci 1996; 19: 312Y8.
61. Stoll G, Jander S. The role of microglia and macrophages in the
pathophysiology of the CNS. Prog Neurobiol 1999; 58: 233Y47.
62. Perry VH. Modulation of microglia phenotype. Neuropathol Appl
Neurobiol 1994; 20: 177.
63. Wall PD, Devor M, Inbal R et al. Autotomy following peripheral
nerve lesions: Experimental anaesthesia dolorosa. Pain 1979; 7:
103Y11.
64. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that
produces disorders of pain sensation like those seen in man. Pain
1988; 33: 87Y107.
65. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of
neuropathic pain disorders produced in rats by partial sciatic nerve
injury. Pain 1990; 43: 205Y18.
66. Kim SH, Chung JM. An experimental model for peripheral
neuropathy produced by segmental spinal nerve ligation in the rat.
Pain 1992; 50: 355Y63.
67. Decosterd I, Woolf CJ. Spared nerve injury: An animal model of
persistent peripheral neuropathic pain. Pain 2000; 87: 149Y58.
68. Eriksson NP, Persson JK, Svensson M et al. A quantitative analysis
of the microglial cell reaction in central primary sensory projection
territories following peripheral nerve injury in the adult rat. Exp
Brain Res 1993; 96: 19Y27.
6 9 . C o l b u r nR W ,D e L e oJ A ,R i c k m a nA Je ta l .D i s s o c i a t i o no f
microglial activation and neuropathic pain behaviors following
peripheral nerve injury in the rat. J Neuroimmunol 1997; 79: 163Y75.
70. Coyle DE. Partial peripheral nerve injury leads to activation of
astroglia and microglia which parallels the development of allodynic
behavior. Glia 1998; 23: 75Y83.
71. Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of
nerve injury on spinal glial activation and neuropathic pain behavior.
Exp Neurol 1999; 157: 289Y304.
72. Stuesse SL, Cruce WL, Lovell JA et al. Microglial proliferation in
the spinal cord of aged rats with a sciatic nerve injury. Neurosci Lett
2000; 287: 121Y4.
73. Gehrmann J, Banati RB. Microglial turnover in the injured CNS:
Activated microglia undergo delayed DNA fragmentation following
peripheral nerve injury. J Neuropathol Exp Neurol 1995; 54: 680Y8.
74. Liu L, Tornqvist E, Mattsson P et al. Complement and clusterin in
the spinal cord dorsal horn and gracile nucleus following sciatic
nerve injury in the adult rat. Neuroscience 1995; 68: 167Y79.
75. Watkins LR, Milligan ED, Maier SF. Glial activation: A driving
force for pathological pain. Trends Neurosci 2001; 24: 450Y5.
76. Surprenant A, Rassendren F, Kawashima E et al. The cytolytic P2Z
receptor for extracellular ATP identified as a P2X receptor (P2X7).
Science 1996; 272: 735Y8.
77. Khakh BS, Burnstock G, Kennedy C et al. International union of
pharmacology. XXIV. Current status of the nomenclature and
properties of P2X receptors and their subunits. Pharmacol Rev
2001; 53: 107Y18.
78. Virginio C, Robertson G, Surprenant A et al. Trinitrophenyl-
substituted nucleotides are potent antagonists selective for P2X1,
P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol 1998; 53:
969Y73.
79. Inoue K, Nakajima K, Morimoto T et al. ATP stimulation of
Ca
2+-dependent plasminogen release from cultured microglia. Br J
Pharmacol 1998; 123: 1304Y10.
80. Hide I, Tanaka M, Inoue A et al. Extracellular ATP triggers tumor
necrosis factor-alpha release from rat microglia. J Neurochem 2000;
75: 965Y72.
81. Suzuki T, Hide I, Ido K et al. Production and release of neuro-
protective tumor necrosis factor by P2X7 receptor-activated micro-
glia. J Neurosci 2004; 24: 1Y7.
82. Shigemoto-Mogami Y, Koizumi S, Tsuda M et al. Mechanisms
underlying extracellular ATP-evoked interleukin-6 release in mouse
microglial cell line, MG-5. J Neurochem 2001; 78: 1339Y49.
83. Ono K, Han J. The p38 signal transduction pathway: Activation and
function. Cell Signal 2000; 12: 1Y13.
84. Jin SX, Zhuang ZY, Woolf CJ et al. p38 mitogen-activated protein
kinase is activated after a spinal nerve ligation in spinal cord
microglia and dorsal root ganglion neurons and contributes to the
generation of neuropathic pain. J Neurosci 2003; 23: 4017Y22.
85. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y et al. Activation of
p38 mitogen-activated protein kinase in spinal hyperactive microglia
contributes to pain hypersensitivity following peripheral nerve
injury. Glia 2004; 45: 89Y95.
86. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor
antagonist in combination with soluble tumor necrosis factor
receptor exhibits an anti-allodynic action in a rat model of
neuropathic pain. Neuroscience 2001; 103: 529Y39.
87. Winkelstein BA, Rutkowski MD, Sweitzer SM et al. Nerve injury
proximal or distal to the DRG induces similar spinal glial activation
and selective cytokine expression but differential behavioral re-
sponses to pharmacologic treatment. J Comp Neurol 2001; 439:
127Y39.
88. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial acti-
vation attenuates the development but not existing hypersensitivity in
a rat model of neuropathy. J Pharmacol Exp Ther 2003; 306: 624Y30.
89. Robertson B, Xu XJ, Hao JX et al. Interferon-gamma receptors in
nociceptive pathways: Role in neuropathic pain-related behaviour.
Neuroreport 1997; 8: 1311Y6.
90. DeLeo JA, Yezierski RP. The role of neuroinflammation and
neuroimmune activation in persistent pain. Pain 2001; 90: 1Y6.
91. Kerr BJ, Bradbury EJ, Bennett DL et al. Brain-derived neurotrophic
factor modulates nociceptive sensory inputs and NMDA-evoked
responses in the rat spinal cord. J Neurosci 1999; 19: 5138Y48.
92. Thompson SW, Bennett DL, Kerr BJ et al. Brain-derived neuro-
trophic factor is an endogenous modulator of nociceptive responses
in the spinal cord. Proc Natl Acad Sci USA 1999; 96: 7714Y8.
93. Vikman KS, Hill RH, Backstrom E et al. Interferon-gamma induces
characteristics of central sensitization in spinal dorsal horn neurons
in vitro. Pain 2003; 106: 241Y51.
94. Viviani B, Bartesaghi S, Gardoni F et al. Interleukin-1beta enhances
NMDA receptor-mediated intracellular calcium increase through
activation of the Src family of kinases. J Neurosci 2003; 23:
8692Y700.
95. Yu XM, Askalan R, Keil GJ, II et al. NMDA channel regulation by
channel-associated protein tyrosine kinase Src. Science 1997; 275:
674Y8.
96. Wang S, Cheng Q, Malik S et al. Interleukin-1beta inhibits gamma-
aminobutyric acid type A (GABA(A)) receptor current in cultured
hippocampal neurons. J Pharmacol Exp Ther 2000; 292: 497Y504.
97. Moriguchi S, Mizoguchi Y, Tomimatsu Y et al. Potentiation of
NMDA receptor-mediated synaptic responses by microglia. Brain
Res Mol Brain Res 2003; 119: 160Y9.
98. Watkins LR, Maier SF. GLIA: A novel drug discovery target for
clinical pain. Nat Rev Drug Discov 2003; 2: 973Y85.
100 K. Inoue et al.